Pipeline
EM Imaging radiopharmaceuticals portfolio
Edinburgh Molecular Imaging has a portfolio of agents designed to improve detection and treatment of Cancer. All Agents progressed to date have been found to be safe, specific, sensitive and selective.
PET Imaging
Therapy
Indications to be disclosed at a later stage.
About Us
EM Imaging was founded in 2014 to develop a versatile and disease focused approach to optical tracer and therapeutic compounds development.
Edinburgh Molecular Imaging Ltd.
Nine
9 Little France Road
Edinburgh BioQuarter (Gate 3)
Edinburgh EH16 4UX
United Kingdom
Recent News
Results published by Investigator on non-invasive assessment of c-MET expression in non-small cell lung cancer
Results published by Investigator on identification and validation of MET as target for fluorescent guided surgery in papillary thyroid cancer
Results published by Investigator on first-in-human biodistribution and first PET imaging results of [Ga-68]EMP-100 in metastatic renal cell carcinoma
Edinburgh Molecular Imaging – 2021